AvenCell Therapeutics
Biotechnology company developing next-generation universal (allogeneic) CAR-T cell therapies for cancer treatment, aiming to make cell therapy more accessible and affordable.
Notes
AvenCell Therapeutics is a Berlin-based biotechnology company focused on developing allogeneic (off-the-shelf) CAR-T cell therapies for cancer treatment. Unlike traditional autologous CAR-T therapies that require manufacturing cells from each patient, AvenCell's universal approach uses donor cells that can be manufactured at scale and made available immediately to patients.
The company spun out from the Max Delbrück Center for Molecular Medicine (MDC) and Charité – Universitätsmedizin Berlin, leveraging decades of cell therapy research from these leading German research institutions.
Team
- Achim Pluecker, Ph.D. - CEO
- Wolfgang Uckert, Ph.D. - Scientific Founder (Professor at Charité and MDC Berlin)
Additional Research Findings
- Backed by Novo Holdings
- Spun out from Max Delbrück Center and Charité Berlin
- Focus on universal/allogeneic CAR-T cell therapies
- Off-the-shelf approach for faster patient access
- Manufacturing scale advantages over autologous therapies
- German cell therapy leader
- Targeting multiple oncology indications
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Novo Holdings | Hellerup, Denmark | biotech-focused | seedseries-a+3 | 13 |